Black Rock Inc. Vaxxinity, Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.62 - $0.86 $56,335 - $78,143	-90,864 Reduced 3.35%	2,623,052 $1.89 Million
Q4 2023 Feb 13, 2024	BUY	$0.7 - $1.31 $130,875 - $244,924	186,965 Added 7.4%	2,713,916 $2.31 Million
Q3 2023 Nov 13, 2023	BUY	$1.25 - $3.0 $193,678 - $464,829	154,943 Added 6.53%	2,526,951 $3.46 Million
Q2 2023 Aug 11, 2023	BUY	$1.73 - $2.79 $3.46 Million - $5.58 Million	1,998,747 Added 535.48%	2,372,008 $5.98 Million
Q3 2022 Nov 14, 2022	BUY	$1.64 - $2.48 $612,148 - $925,687	373,261 New	373,261 $739,000

469K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $1.12M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.